Form 4: TransMedics Group CFO Stephen Gordon Executes Stock Option and Sells Shares
SEC Form 4 Filing
Stephen Gordon, CFO of TransMedics Group, exercised stock options and sold 15,000 shares of common stock on March 4, 2024, according to a recent SEC filing.
Summary
- On March 4, 2024, Stephen Gordon, the Chief Financial Officer of TransMedics Group, Inc. (TMDX), executed a stock option to acquire 15,000 shares of common stock at a price of $38.46 per share.
- Simultaneously, Gordon sold 15,000 shares of common stock at a price of $82.8 per share.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on September 14, 2023.
- Following these transactions, Gordon directly owns 25,202 shares of common stock and 52,477 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects routine insider trading activity under a pre-arranged plan. There is no indication of positive or negative implications for the company.
Industry Context
This filing is a routine disclosure of insider transactions and provides transparency to investors regarding the actions of company executives. It is common for executives to have pre-arranged trading plans to avoid accusations of insider trading.
Key Dates
| Date | Description |
|---|---|
| 09/14/2023 | Date of establishment of Rule 10b5-1 trading plan |
| 02/24/2025 | Date the option is fully vested |
| 02/24/2031 | Expiration date of the stock option |
| 03/04/2024 | Date of stock option exercise and share sale |
| 03/05/2024 | Date of signature on the SEC Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.